Regulatory T-Cells in Treatment of Type-1 Diabetes: Types and Approaches
Journal Title: Diabetes Research – Open Journal - Year 2015, Vol 1, Issue 3
Abstract
Regulatory T-cells (Tregs) play important role in regulation of immune responses to self-antigens. Alterations in frequency and function of Tregs have been reported in Type 1 Diabetes (T1D) subjects. Tregs have the potential to prevent destruction of pancreatic beta cells by targeting effector T-cells (Teff) and other immune cells causing inflammation. Therefore, strategies to increase Treg cell numbers and function are being explored as potential immunotherapeutic approaches in treating T1D. Today, several groups are involved in exploring different Treg cell types, sources, induction procedures and experimental systems in pursuit of generation of highly efficacious and stable Tregs for their clinical applications. Various protocols have been developed for the induction and expansion of islet antigen specific Tregs and polyclonal Tregs. Studies have shown that antigen specific Tregs are required at less number and are more efficient than polyclonal Tregs in suppressing autoimmune diabetes and they do not cause generalized immune suppression. Alternatively, generation of colonic Tregs (cTregs) has also gathered attention in recent years as an approach to limit pancreatic inflammation via gut induced tolerance. With a definitive treatment for T1D still elusive, application of Tregs as a part of combination therapy seems promising in treatment of T1D.
Authors and Affiliations
Naresh Sachdeva
Keywords
Related Articles
- EP ID EP550042
- DOI 10.17140/DROJ-1-109
- Views 142
- Downloads 0
Type 1 Diabetes Update at Children With Diabetes Community
Of the estimated 415 million people living with diabetes worldwide, 10% have Type 1 Diabetes (T1D) meaning they will remain insulin dependent until a cure is found. Globally, we can observe an increasing trend of about 5...
Comparison of Diuretic Effects between Empagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor With Osmotic Diuresis, and Tolvaptan, a Water Diuretic, in Two Type 2 Diabetic Patients Taking Sodium Diuretics
Empagliflozin, one of sodium-glucose co-transporter 2 (SGLT2) inhibitors, has been demonstrated to have beneficial effects on cardiovascular morbidity and mortality in patients with type 2 diabetes at high risk for cardi...
Diabetes in the Northwest Territories
An estimated 2.7 million (7.6%) Canadians were living with diabetes in 2012.1 Internationally, Canada has the fourth highest rate of diabetes, behind Mexico, the United States and Portugal.2 The prevalence of diabetes...
Intestinal Parasites in Diabetes Mellitus Patients in the Limbe and Buea Municipalities, Cameroon
Background: Intestinal parasites are an important cause of morbidity and mortality and a public health problem especially in tropical developing countries including Cameroon. The two main types of intestinal parasites ar...
Association of Total and Differential White Blood Cell Counts to Development of Type 2 Diabetes in Mexican Americans in Cameron County Hispanic Cohort
Objective: To evaluate the relationship between total and differential White Blood Cells (WBC) counts with time to transition to type 2 diabetes in Mexican Americans using prospective data from the Cameron County Hispani...